Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BIOTRONIK AG
The US FDA cleared the Vital Data Sensor, which identifies body temperature increases that can indicate a fever caused by an infection.
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
Acute ST-elevation myocardial infarction patients treated with Biotronik’s Orsiro biodegradable polymer sirolimus-eluting stent had a significantly lower rate of target vessel failure than patients treated with Abbott’s Xience durable polymer everolimus-eluting stent at the one-year follow-up in the BIOSTEMI trial.
The company says Biomonitor III documents suspected arrhythmias or unexplained syncope in patients who have experienced cardiac arrhythmias or who are at risk for cardiac arrhythmias.
- Medical Devices
- Drug Delivery
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive